Recently, the sub-center kick-off meetings for the Phase II Clinical Trial of Nolgileucel (GC101), the world's first TIL therapy that does not require high-intensity lymphodepletion chemotherapy or the administration of IL-2 developed by Shanghai Juncell Therapeutics Co., Ltd, for the treatment of advanced non-small cell lung cancer (MIZAR-005) were successively held at Zhejiang Cancer Hospital, Fujian Cancer Hospital, Chongqing University Cancer Hospital, Peking University People's Hospital, and the First Affiliated Hospital of Guangzhou Medical University.

Covering East China, Southeast China, South China, Southwest China and North China, this initiative marks the continued advancement of the nationwide multi-center clinical trial network for MIZAR-005.

Professor Song Zhengbo, Director of the Department of Thoracic Oncology at Zhejiang Cancer Hospital, Professor He Zhiyong, Deputy Director of the Department of Medical Oncology at Fujian Cancer Hospital, Professor  Li Yongsheng, Director of the Department of Medical Oncology at Chongqing University Cancer Hospital, Professor Yan Xiang, Deputy Director of the Lung Cancer Center at Peking University People's Hospital, Professor Zhou Chengzhi, Vice President of the First Affiliated Hospital of Guangzhou Medical University, and the relevant clinical research teams, along with Lin Shuwei, Vice President of Juncell and the company's clinical team, participated in the sitekick-off meetings respectively.